China Coronary Secondary Prevention Study
cholesterol level in the Xuezhikang group control group died from all causes, the risk was declined for 6 to 8 weeks and then stabilized. 33.0% lower in Xuezhikang group than in Cholesterol level in the Xuezhikang group was placebo controls (P=0.0003). The beneficial 13.2% lower than that of the control group after effect of Xuezhikang in reducing deaths can be 3.5 years (P<0.001). The baseline LDL-C observed after a half year of treatment (figure 4),. levels in the Xuezhikang and control groups This benefit continued to increase during the were 3.33 ±0.73 mmol/L and 3.34 ± 0.74 remainder of the follow-up period.
Table 4 also shows Xuezhikang related mmol/L respectively. LDL-C level fell by
20.2% after average 3.5 years of treatment compared to 3.5 % reduction in the control group(P<0.001). Xuezhikang also resulted in significant reductions in TG levels (P<0.001)and
increases in HDL-C levels (P=0.0006)after 3.5
years.
Clinical Events
Table 4 shows the incidence of CHD and other events in the Xuezhikang and control groups. The primary end-point was CHD events, including nonfatal and fatal acute MI, sudden CHD death and other CHD death. Xuezhikang decreased the risk of CHD events by 45.1 % compared with placebo. (P<0.0001)
Xuezhikang resulted in CHD incidence reduction
within half a year of treatment. The improvement in CHD prognosis continued to increase during the remainder of the follow-up
period. (figure1-3). There were 47 cases (1.93%) of non-fatal acute MI in the Xuezhikang
group, and 120 (4.92%) in the control group.
Risk reduction for non-fatal MI was 60.8% (P<0.0001). Xuezhikang also reduced risk for fatal acute MI (32.2%, P=0.1928), CHD sudden death (23.4%,, P=0.1432), overall other CHD
death (43.1%, P=0.0299), and total CHD death (31.0%, P=0.0048). As compared with patients given placebo, both men and women treated with Xuezgikang
had significantly lower rates of CHD events. The
effect of Xuezhikang on the rate of CHD events
was not substantially altered by the variable at
baseline(Table 5).
The secondary endpoint was all-cause mortality, 126 (5.19%) patients in the Xuezhikang group and 189 (7.74%) in the reductions in fatal and non fatal malignancies, stroke, and need for coronary interventions. Safety
There were 43 (1.77%) reported adverse events in the Xuezhikang group and 39 (1.60%) in the control group, (P=0.6842). Common adverse events in both groups included gastrointestinal disorders, allergic reactions, mental-neurological symptoms, myoparesis and myodynia. There were no significant differences in adverse events or laboratory test results in the two groups. COMMENT
This study demonstrated that therapy with Xuezhikang can significantly reduce the risk of coronary events in Chinese patients with CHD. The results of the study suggest that treating
1000 Chinese CHD patients with Xuezhikang for 4 years would eliminate 47 recurrent CHD
events, including 17 CHD deaths and 30 non-fatal acute MIs. Xuezhikang also would reduce the number of strokes and other vascular events. In addition to the cardiovascular benefits, Xuezhikang would eliminate 26 cases
of all-cause death per 1000 patients. Xuezhikang did not result in excess adverse events or laboratory abnormalities when compared to placebo.
Xuezhikang also reduced the risk of fatal malignancies by 55% (P=0.00138). A previous study indicated that pravastatin therapy in elderly patients was associated with an a 25 % increased risk of gastrointestinal malignancies[5]. A meta-analysis regarding statin use and malignancies in CHD prevention studies showed there was no elevation in the risk of malignancy.
China Coronary Secondary Prevention Study (CCSPS) - Lipid-regulating_英语学习_外语学习_教育专区 暂无评价 0人阅读 0次下载 举报文档 China Coronary ...
Feasibility Study of W... 18页 免费 China Coronary Seconda... 暂无评价...After secondary polymer flooding, just as shown in Table 3, fractional flow...
(二)冠心病二级预防研究 1.中国冠心病二级预防研究(China Coronary Secondary Prevention Study, CCSPS)[26-27] 目前这是我国惟一一项对冠心病二级预防的大规模,前瞻...
9. 中国冠心病二级预防研究(China coronary secondary prevention study,CCSPS): 研究表明老年患者、合并糖尿病或高血压的患者治疗后获益更显著。 特殊人群的降脂临床...
我国从1996年至2000年进 行的中国冠心病二级预防研究(China Coronary Secondary Prevention Study CCSPS)是针对中国冠心病患者进行的冠心病二级预防试验, 是一项为多...
Chapter 6 Secondary synt... 暂无评价 37页 免费 Spoofing Prevention Meth... 暂无评价 18页 免费 China Coronary Secondary... 暂无评价 11页 免费...
血脂与冠心病 ——来自中国循证医学的证据解放军总医院 叶平 CCSPS 中国冠心病二级预防研究 China Coronary Secondary Prevention Study (CCSPS) --血脂康调整血脂对...
coronary heart disease.4 In the past 20 years,...“primary prevention”, “secondary prevention”, ...study in China and it showed the lowest average...
血脂康调整血脂 对冠心病二级预防的研究 China Coronary Secondary Prevention Study (CCSPS) CCSPS) 国家九五攻关课题编号:96-906-02国家九五攻关课题编号:96-906-...
中国冠心病二级预防研究 China Coronary Secondary Prevention Study 中国老年冠心病人群唯一循证医学研究(国家九五攻关课题) 课题牵头单位:阜外心血管病医院课题协作单位:...
热门文档